SCPS - Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer | Benzinga
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: "SCPS"), a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioTherapeutics Inc., which is developing novel immunotherapies to overcome treatment-resistant cancers, today announced that Marcin Kortylewski, Ph.D., Co-Founder and Senior Scientific Advisor of Duet and Professor of Immuno-Oncology at City of Hope, will be presenting at the 38th Annual Meeting of the Society for Immunotherapy of Cancer ("SITC"). SITC is being held from November 3-5, 2023, in San Diego, California.
Details of the presentation are as follows:
Title: Reprograming of Tumor-associated Myeloid Cells by TLR9-targeted STAT3 Antisense Oligonucleotides Sensitizes Malignant Glioma to PD1-specific Immunotherapy
Presentation Type: Poster
Presenter: Marcin Kortylewski, Ph.D., Duet BioTherapeutics; City of Hope
Session: Poster Reception
Poster Board Number: 812
Session Date/Time: Saturday, November 4, 2023, 7:00 PM – 8:30 PM ...